

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Ikano Therapeutics, Inc.	FORMERLY known as "Intranasal Therapeutics, Incorporated"	02/12/2009	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	Silicon Valley Bank, as Collateral Agent and as a Lender
Street Address:	3003 Tasman Drive
City:	Santa Clara
State/Country:	CALIFORNIA
Postal Code:	95054
Entity Type:	Bank: CALIFORNIA

Name:	Oxford Finance Corporation, as a Lender
Street Address:	133 North Fairfax St.
City:	Alexandria
State/Country:	VIRGINIA
Postal Code:	22314
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 2

Property Type	Number	Word Mark
Serial Number:	78839803	ESSPRAYGO
Serial Number:	78839835	FLASH

CORRESPONDENCE DATA

Fax Number: (703)415-1557
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 703-415-1555
 Email: mail@specializedpatent.com
 Correspondent Name: Christopher E. Kondracki

CH \$65.00 78839803

Address Line 1: 2001 Jefferson Davis, Hwy., Suite 1007
Address Line 4: Arlington, VIRGINIA 22202

ATTORNEY DOCKET NUMBER:	9050801
NAME OF SUBMITTER:	Christopher E. Kondracki
Signature:	/Christopher E. Kondracki/
Date:	06/23/2009

Total Attachments: 9
source=Ikano - 6-12#page1.tif
source=Ikano - 6-12#page2.tif
source=Ikano - 6-12#page3.tif
source=Ikano - 6-12#page4.tif
source=Ikano - 6-12#page5.tif
source=Ikano - 6-12#page6.tif
source=Ikano - 6-12#page7.tif
source=Ikano - 6-12#page8.tif
source=Ikano - 6-12#page9.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as February 12, 2009 by and among **SILICON VALLEY BANK**, a California corporation with a loan production office located at One Newton Executive Park, Suite 200, 2221 Washington Street, Newton, Massachusetts 02462 ("**SVB**"), as agent (the "**Collateral Agent**"), the Lenders, including without limitation, SVB, and **OXFORD FINANCE CORPORATION ("Oxford")**, and **IKANO THERAPEUTICS, INC.** (formerly known as "Intranasal Therapeutics, Incorporated"), a Delaware corporation ("**Grantor**").

RECITALS

A. Lenders agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the "**Loans**") in the amounts and manner set forth in that certain Loan and Security Agreement by and among Lenders and Grantor dated as of September 28, 2007, as amended by that certain First Loan Modification Agreement by and among Lenders and Grantor dated as of October 10, 2007, as further amended by a certain Second Loan Modification Agreement by and among the Lenders and Grantor dated as of even date hereof (as the same may be amended, modified or supplemented from time to time, the "**Loan Agreement**"; capitalized terms used herein are used as defined in the Loan Agreement). Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the ratable benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of Grantor under the Loan Agreement.

B. Notwithstanding the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of which shall collectively be called the "**Intellectual Property Collateral**"), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the "Mask Works");

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the ratable benefit of the Lenders under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Collateral Agent, of any or all other rights, powers or remedies.

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.


GRANTOR:

Address of Grantor:

Park 80 West-Plaza Two, Suite 310
250 Peble Avenue
Saddle Brook, NJ 07663

Attn: Pat Fabbis
CFO

IKANO THERAPEUTICS, INC. (formerly known as "Intranasal Therapeutics, Incorporated")

By: 
Title: President/CEO

LENDERS:

Address of Lender:

SILICON VALLEY BANK, AS
COLLATERAL AGENT AND AS A LENDER

By: _____

Title: _____

Attn: _____

Address of Lender:

OXFORD FINANCE CORPORATION, AS A
LENDER

By: _____

Title: _____

Attn: _____

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

IKANO THERAPEUTICS, INC. (formerly known as "Intranasal Therapeutics, Incorporated")

By: _____

Attn: _____

Title: _____

LENDERS:

Address of Lender:

SILICON VALLEY BANK, AS COLLATERAL AGENT AND AS A LENDER

Attn: Bernadette Mizhaud
Silicon Valley Bank
2221 Washington St.
One Newton Executive Park
Newton, MA 02462

By:  _____

Attn: _____

Title: VP _____

Address of Lender:

OXFORD FINANCE CORPORATION, AS A LENDER

By: _____

Attn: _____

Title: _____

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

IKANO THERAPEUTICS, INC. (formerly known as "Intranasal Therapeutics, Incorporated")

By: _____

Attn: _____

Title: _____

LENDERS:

Address of Lender:

SILICON VALLEY BANK, AS COLLATERAL AGENT AND AS A LENDER

By: _____


Attn: _____

Title: _____

Address of Lender:

133 North Fairfax St.
Alexandria, VA 22314

OXFORD FINANCE CORPORATION, AS A LENDER

By: 

Attn: General Counsel

Title: VP & General Counsel

EXHIBIT A

Copyrights

None

EXHIBIT B

Patents

mPEG – Patent Rights Co-owned by Grantor

Our Ref.	Country	Patent / Application No.	Filing Date
INT-010	US	12/016,724	01/18/2008
INT-010PC	WO	PCT/US08/51466	01/18/2008

MELATONIN RECEPTOR ANTAGONIST – Patent Rights Owned by Grantor

Our Ref.	Country	Patent / Application No.	Filing Date
INT-005PR	US	60/782,761	03/16/2006
INT-005PC	WO	PCT/US07/06657	03/16/2007
INT-005	US	12/293,197	09/16/2008

REPAGLINIDE – Patent Rights Owned by Grantor

Our Ref.	Country	Patent / Application No.	Filing Date
INT-006PR	US	60/784,946	03/22/2006
INT-006PC	WO	PCT/US07/07102	03/22/2007
INT-006	US	12/293,843	09/22/2008

NALTREXONE – Patent Rights Co-owned by Grantor

Our Ref.	Country	Patent / Application No.	Filing Date
INT-004PR	US	60/771,995	02/10/2006
INT-004	US	11/673,874	02/12/2007

EXHIBIT C

Trademarks

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
ESSPRAYGO	78-839803	Filing Date: March 17, 2006
FLASH	78-839835	Filing Date: March 17, 2006

EXHIBIT D

Mask Works

None

1129758.4